Drug Profile
Magnetic resonance imaging contrast agent - Theragnostic Technologies
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Theragnostic Technologies
- Class Contrast media
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cardiovascular disorders; Coronary disorders; Gastrointestinal disorders; Kidney disorders; Renal failure; Vascular disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Renal-failure(Diagnosis) in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Breast-cancer(Diagnosis) in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cardiovascular-disorders(Diagnosis) in USA